Dopamine D3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider?

被引：4
|
作者：
Hernandez-Huerta, Daniel [1 ]
Morillo-Gonzalez, Jessenia [1 ]
机构：
[1] Ramon y Cajal Univ Hosp, Dept Psychiat, Madrid, Spain
来源：
CNS SPECTRUMS | 2021年 / 26卷 / 05期
关键词：
D O I：
10.1017/S1092852920001510
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：444 / 445
页数：2
相关论文
共 50 条
  • [21] Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders
    Heidbreder, Christian
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 (02) : 167 - 176
  • [22] Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders
    Christian Heidbreder
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386 : 167 - 176
  • [23] Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges
    Galaj, Ewa
    Newman, Amy Hauck
    Xi, Zheng-Xiong
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2020, 114 : 38 - 52
  • [24] Pharmacological treatment of Parkinson’s disease: life beyond dopamine D2/D3 receptors?
    G. Linazasoro
    N. Van Blercom
    L. Ugedo
    J. A. Ruiz Ortega
    Journal of Neural Transmission, 2008, 115 : 431 - 441
  • [25] Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?
    Linazasoro, G.
    Van Blercom, N.
    Ugedo, L.
    Ortega, J. A. Ruiz
    JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (03) : 431 - 441
  • [26] Evidence for D3 Subtype Receptors as the Target of Dopamine-Agonists in the Treatment of Restless Legs Syndrome
    Manconi, Mauro
    Ferri, Raffaele
    Bassetti, Claudio
    Zucconi, Marco
    Ferini-Strambi, Luigi
    NEUROLOGY, 2011, 76 (09) : A595 - A595
  • [27] Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment
    Kumar, Vivek
    Bonifazi, Alessandro
    Ellenberger, Michael P.
    Keck, Thomas M.
    Pommier, Elie
    Rais, Rana
    Slusher, Barbara S.
    Gardner, Eliot
    You, Zhi-Bing
    Xi, Zheng-Xiong
    Newman, Amy Hauck
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (16) : 7634 - 7650
  • [28] Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys
    Paul W. Czoty
    H. Donald Gage
    Pradeep K. Garg
    Sudha Garg
    Michael A. Nader
    Psychopharmacology, 2014, 231 : 613 - 619
  • [29] Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys
    Czoty, Paul W.
    Gage, H. Donald
    Garg, Pradeep K.
    Garg, Sudha
    Nader, Michael A.
    PSYCHOPHARMACOLOGY, 2014, 231 (03) : 613 - 619
  • [30] Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor
    Dinkins, Mai-Lynne
    Lallemand, Perrine
    Clemens, Stefan
    SLEEP MEDICINE, 2017, 40 : 47 - 52
12345